You are viewing a single comment's thread.

view the rest of the comments →

MercurysBall2 ago

Outward Bound Global officers https://beta.companieshouse.gov.uk/company/00405180/officers

Dame Pamela Louise Makin, DBE (born November 1960) is a British businesswoman, the chief executive (CEO) of BTG plc, a FTSE 250 Index healthcare company.

Makin has been the chief executive officer of BTG PLC since 17 September 2004. She served as the president for biopharmaceuticals Europe at Baxter Healthcare since 2001, where she was responsible for sales in Europe, Africa and the Middle East. Makin joined Baxter Healthcare in 2000 as vice president of strategy and business development Europe.

MercurysBall2 ago

Dame Pamela Louise Makin has been a non-executive director of Intertek Group plc since 1 July 2012.

Here https://www.lsxleaders.com/lifestars-awards/lifetime-achievement

Dame Louise Makin, MA, PhD (Cantab), MBA, DBE, joined BTG as Chief Executive Officer in October 2004 and led the transformation of BTG from $150m value to acquisition by Boston Scientific for $4.2 billion in August 2019 by successfully acquiring and integrating 8 companies into BTG to create a leading Interventional Medicine Business. Louise is a non-executive director of Intertek Group plc and the Woodford Patient Capital Trust, a Trustee of the Outward Bound Trust, Chair of the 1851 Trust, and an Honorary Fellow of St. John’s College, Cambridge.

Intertek was involved with the Monsanto controversy https://www.cbc.ca/news/health/glyphosate-monsanto-intertek-studies-1.4902229

In March 2015, agrochemical giant Monsanto had a problem. The World Health Organization's International Agency for Research on Cancer (IARC) announced that glyphosate, the principal ingredient in Monsanto's Roundup weed-killer product, was probably carcinogenic to humans.

The documents also reveal communications between Monsanto and a Canadian firm hired to recruit scientists to publish studies that ultimately defended glyphosate — some of which were secretly reviewed by Monsanto prior to publication. All those papers, as previously reported by CBC/Radio-Canada, were also used as part of Health Canada's re-approval process of glyphosate in 2017.

..Five studies, including a review article, were eventually written and published in 2016. Monsanto hired Intertek, formerly known as Cantox of Mississauga, Ont., to set and co-ordinate four "independent expert panels" to publish these papers in the journal, Critical Reviews in Toxicology. The 15 researchers concluded unanimously that glyphosate was not a carcinogen.

.Those papers got noticed by federal regulators. In defending its decision to re-approve use of glyphosate in 2017, Health Canada cited those papers in its list of references. It re-approved glyphosate until 2032, a decision based in large part on studies written by industry.

Internal Monsanto emails show that the company closely followed the evolution of some of the articles and even edited passages.

On Jan. 6, 2016, company official Heydens writes to Intertek about one of the papers (pdf link): "I think you and I should talk about how that chapter gets completed, as it is not exactly what I was expecting."